The application of RNAi-based treatments for inflammatory bowel disease

Drug Delivery and Translational Research

Volumn 4, Issue 1, 2014, Pages 4-18

  Olesen, Morten Tobias Jarlstad ^a   Ballarín González, Borja ^a   Howard, Kenneth Alan ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Clinical translation; Crohn's disease; Inflammatory bowel disease; RNAi; siRNA; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; SMALL INTERFERING RNA;

CROHN DISEASE; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MEDICAL TECHNOLOGY; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; ULCERATIVE COLITIS;

EID: 84893610897     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0156-9     Document Type: Review

References (160)

1. Louis E, van Kemseke C, Reenaers C. Necessity of phenotypic classification of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2011;25 Suppl 1: S2-7. doi: 10. 1016/s1521-6918(11)70003-8.
2. Vermeire S, van Assche G, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol. 2012;28(4): 321-6. doi: 10. 1097/MOG. 0b013e328354be1e.
3. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7): 521-33. doi: 10. 1038/nri1132.
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6): 417-29. doi: 10. 1056/NEJMra020831.
5. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Investig. 2007;117(3): 514-21. doi: 10. 1172/jci30587.
6. Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161(2): 235-46. doi: 10. 1016/j. jconrel. 2012. 01. 028.
7. Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72(18): 2333-49. doi: 10. 2165/11638120-000000000-00000.
8. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6): 1785-94. doi: 10. 1053/j. gastro. 2011. 01. 055.
9. Gersemann M, Stange EF, Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol. 2011;17(27): 3198-203. doi: 10. 3748/wjg. v17. i27. 3198.
10. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351): 307-17. doi: 10. 1038/nature10209.
11. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78(1): 127-31.
12. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol (Baltimore, Md: 1950). 1996;157(3): 1261-70.
13. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150(3): 823-32.
14. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1): 65-70.
15. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12(1): 9-15.
16. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6): 1756-67. doi: 10. 1053/j. gastro. 2011. 02. 016.
17. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Investig. 2004;113(10): 1490-7. doi: 10. 1172/jci19836.
18. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86(2): 202-10.
19. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol (Baltimore, Md: 1950). 1993;150(6): 2487-93.
20. Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, et al. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci. 2002;47(6): 1349-55.
21. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol. 2010;10(10): 735-44. doi: 10. 1038/nri2850.
22. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin N Am. 2004;33(2): 335-45. doi: 10. 1016/j. gtc. 2004. 02. 006.
23. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5: 185-210. doi: 10. 2147/DDDT. S11290.
24. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55(2): 205-11. doi: 10. 1136/gut. 2005. 073817.
25. Lepage P, Hasler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141(1): 227-36. doi: 10. 1053/j. gastro. 2011. 04. 011.
26. Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(4): e794-803. doi: 10. 1542/peds. 2011-3886.
27. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006;343(1): 69-76. doi: 10. 1016/j. bbrc. 2006. 02. 080.
28. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci. 2009;54(2): 255-63. doi: 10. 1007/s10620-008-0357-0.
29. Kho M, Cransberg K, Weimar W, van Gelder T. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother. 2011;12(8): 1217-31. doi: 10. 1517/14656566. 2011. 552428.
30. Satoh Y, Ishiguro Y, Sakuraba H, Kawaguchi S, Hiraga H, Fukuda S, et al. Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling. Am J Physiol Gastrointest Liver Physiol. 2009;297(3): G514-9. doi: 10. 1152/ajpgi. 90608. 2008.
31. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24(2): 157-65. doi: 10. 1016/j. bpg. 2009. 10. 011.
32. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111(8): 641-9.
33. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3): 160-70. doi: 10. 1038/ncpgasthep0696.
34. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 1981;22(8): 642-7.
35. Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther. 1995;272(1): 399-406.
36. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991;32(1): 50-4.
37. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3): 602-9.
38. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8): 1205-15. doi: 10. 1084/jem. 20041948.
39. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006;27(12): 2371-82. doi: 10. 1093/carcin/bgl071.
40. Chen J, Huang XF. Beta-catenin pathway in ulcerative colitis-associated colorectal cancer and therapeutic implication. J Gastrointest Cancer. 2009;40(1-2): 64-5. doi: 10. 1007/s12029-009-9070-2.
41. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(6): 1827-37. 10. 1053/j. gastro. 2011. 02. 045.
42. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125(10-11): 697-706. doi: 10. 1016/j. mad. 2004. 06. 010.
43. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol. 2009;296(3): G612-20. doi: 10. 1152/ajpgi. 90576. 2008.
44. Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther. 2001;15(10): 1515-25.
45. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet. 2005;6(1): 24-35.
46. Wassenegger M. The role of the RNAi machinery in heterochromatin formation. Cell. 2005;122(1): 13-6. doi: 10. 1016/j. cell. 2005. 06. 034.
47. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006): 343-9.
48. Waterhouse PM, Wang MB, Lough T. Gene silencing as an adaptive defence against viruses. Nature. 2001;411(6839): 834-42. doi: 10. 1038/35081168.
49. Li H, Li WX, Ding SW. Induction and suppression of RNA silencing by an animal virus. Science. 2002;296(5571): 1319-21. doi: 10. 1126/science. 1070948.
50. Tabara H, Sarkissian M, Kelly WG, Fleenor J, Grishok A, Timmons L, et al. The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell. 1999;99(2): 123-32.
51. Vastenhouw NL, Plasterk RH. RNAi protects the Caenorhabditis elegans germline against transposition. Trends Genet. 2004;20(7): 314-9. doi: 10. 1016/j. tig. 2004. 04. 011.
52. Xie Z, Johansen LK, Gustafson AM, Kasschau KD, Lellis AD, Zilberman D, et al. Genetic and functional diversification of small RNA pathways in plants. PLoS Biol. 2004;2(5): E104. doi: 10. 1371/journal. pbio. 0020104.
53. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol. 2013. doi: 10. 1016/j. jmb. 2013. 03. 007.
54. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669): 806-11.
55. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24): 3011-6. doi: 10. 1101/gad. 1158803.
56. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101(1): 25-33.
57. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell. 2004;118(1): 57-68. doi: 10. 1016/j. cell. 2004. 06. 017.
58. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2): 94-108. doi: 10. 1038/nrg2504.
59. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005;23(2): 222-6. doi: 10. 1038/nbt1051.
60. Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 2005;33(13): 4140-56. doi: 10. 1093/nar/gki732.
61. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998;95(26): 15502-7.
62. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836): 494-8.
63. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6): 443-53. doi: 10. 1038/nrd2310.
64. Davidson BL, McCray Jr PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5): 329-40. doi: 10. 1038/nrg2968.
65. Rahbek UL, Howard KA, Oupicky D, Manickam DS, Dong M, Nielsen AF, et al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J Gene Med. 2008;10(1): 81-93.
66. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9(6): 1327-33.
67. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67(16): 7713-22. doi: 10. 1158/0008-5472. can-07-1083.
68. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7(6): 759-64.
69. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29(11): 1580-7. doi: 10. 1038/onc. 2009. 445.
70. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Ravindra Babu B, Wengel J, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 2007;35(17): 5886-97.
71. C-y C, Rana TM. Potent RNAi by short RNA triggers. RNA. 2008;14(9): 1714-9.
72. Sun X, Rogoff HA, Li CJ. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol. 2008;26(12): 1379-82.
73. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009;17(4): 725-32.
74. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567): 550-3. doi: 10. 1126/science. 1068999.
75. Liu YP, Westerink JT, ter Brake O, Berkhout B. RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy. Methods Mol Biol. 2011;721: 293-311. doi: 10. 1007/978-1-61779-037-9_18.
76. Dissen GA, Lomniczi A, Neff TL, Hobbs TR, Kohama SG, Kroenke CD, et al. In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods. 2009;49(1): 70-7. doi: 10. 1016/j. ymeth. 2009. 06. 004.
77. Liu YP, Dambaeva SV, Dovzhenko OV, Garthwaite MA, Golos TG. Stable plasmid-based siRNA silencing of gene expression in human embryonic stem cells. Stem Cells Dev. 2005;14(5): 487-92. doi: 10. 1089/scd. 2005. 14. 487.
78. Gaspar HB, Thrasher AJ. Gene therapy for severe combined immunodeficiencies. Expert Opin Biol Ther. 2005;5(9): 1175-82. doi: 10. 1517/14712598. 5. 9. 1175.
79. Boudreau RL, Martins I, Davidson BL. Artificial MicroRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2008;17(1): 169-75.
80. Ehlert EM, Eggers R, Niclou SP, Verhaagen J. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci. 2010;11: 20.
81. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441(7092): 537-41.
82. Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 2006;34(17): 4900-11. doi: 10. 1093/nar/gkl464.
83. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol. 2007;365(1): 90-108. doi: 10. 1016/j. jmb. 2006. 09. 034.
84. Hamm S, Latz E, Hangel D, Muller T, Yu P, Golenbock D, et al. Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology. 2010;215(7): 559-69. doi: 10. 1016/j. imbio. 2009. 09. 003.
85. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 2006;12(7): 1197-205.
86. Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjær N, Odadzic D, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010;38(17): 5761-73.
87. Elmén J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1): 439-47.
88. Sipa K, Sochacka E, Kazmierczak-Baranska J, Maszewska M, Janicka M, Nowak G, et al. Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA. 2007;13(8): 1301-16.
89. Li Z-Y, Mao H, Kallick DA, Gorenstein DG. The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem Biophys Res Commun. 2005;329(3): 1026-30.
90. Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, et al. Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA. 2008;14(2): 263-74.
91. Vaish N, Chen F, Seth S, Fosnaugh K, Liu Y, Adami R, et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 2011;39(5): 1823-32.
92. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34(8): 1393-7. doi: 10. 1124/dmd. 106. 009555.
93. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, et al. Human host factors required for influenza virus replication. Nature. 2010;463(7282): 813-7. doi: 10. 1038/nature08699.
94. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291): 1067-70.
95. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen M, et al. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol Ther. 2006;14(4): 476-84.
96. Howard KA, Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin Biol Ther. 2007;7(12): 1811-22.
97. Howard KA. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev. 2009;61(9): 710-20.
98. Rahbek UL, Nielsen AF, Dong M, You Y, Chauchereau A, Oupicky D, et al. Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. J Drug Target. 2010;18(10): 812-20.
99. Liu X, Howard KA, Dong M, Andersen MO, Rahbek UL, Johnsen MG, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 2007;28(6): 1280-8. doi: 10. 1016/j. biomaterials. 2006. 11. 004.
100. Andersen MØ, Howard KA, Paludan SR, Besenbacher F, Kjems J. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials. 2008;29(4): 506-12.
101. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089): 111-4. doi: 10. 1038/nature04688.
102. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2): 172-6. doi: 10. 1038/nbt. 1602.
103. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26(5): 561-9. doi: 10. 1038/nbt1402.
104. Pouton CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Deliv Rev. 2001;46(1-3): 187-203.
105. Ballarín-González B, Nielsen EJ, Thomsen T, Howard K. Mucosal delivery of RNAi therapeutics. In: Howard KA, editor. RNA interference from biology to therapeutics. Advances in delivery science and technology. New York: Springer; 2012. p. 97-125.
106. Ballarin-Gonzalez B, Dagnaes-Hansen F, Fenton RA, Gao S, Hein S, Dong M, et al. Protection and systemic translocation of siRNA following oral administration of chitosan/siRNA nanoparticles. Mol Ther Nucleic Acids. 2013;2: e76. doi: 10. 1038/mtna. 2013. 2.
107. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187): 591-7. doi: 10. 1038/nature06765.
108. Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A. 2009;106(17): 7137-42. doi: 10. 1073/pnas. 0812317106.
109. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004;101(23): 8682-6. doi: 10. 1073/pnas. 0402630101.
110. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004;101(23): 8676-81. doi: 10. 1073/pnas. 0402486101.
111. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther. 2008;19(10): 991-9. doi: 10. 1089/hum. 2008. 131.
112. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2): 131-44. doi: 10. 1038/nri2707.
113. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857): 732-8. doi: 10. 1038/35099560.
114. Heil F. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science. 2004;303(5663): 1526-9.
115. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004;101(15): 5598-603.
116. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-{pipe}[alpha]{pipe} by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11(3): 263-70.
117. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol. 2006;36(5): 1222-30.
118. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 2005;348(5): 1079-90.
119. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23(4): 457-62. doi: 10. 1038/nbt1081.
120. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006;12: 1188-96.
121. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663): 1529-31.
122. Forsbach A, Nemorin JG, Montino C, Müller C, Samulowitz U, Vicari AP, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol. 2008;180(6): 3729-38.
123. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5(9): 834-9. doi: 10. 1038/ncb1038.
124. Zhang Z, Weinschenk T, Guo K, Schluesener HJ. siRNA binding proteins of microglial cells: PKR is an unanticipated ligand. J Cell Biochem. 2006;97(6): 1217-29. doi: 10. 1002/jcb. 20716.
125. Williams BR. Signal integration via PKR. Sci STKE. 2001;2001(89): re2. doi: 10. 1126/stke. 2001. 89. re2.
126. Dever TE. Translation initiation: adept at adapting. Trends Biochem Sci. 1999;24(10): 398-403.
127. Dey M, Cao C, Dar AC, Tamura T, Ozato K, Sicheri F, et al. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2α substrate recognition. Cell. 2005;122(6): 901-13.
128. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 2012;488(7413): 670-4. doi: 10. 1038/nature11290.
129. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science. 2006;314(5801): 997-1001. doi: 10. 1126/science. 1132998.
130. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314(5801): 994-7. doi: 10. 1126/science. 1132505.
131. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008;205(7): 1601-10.
132. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol. 2006;24(5): 559-65. doi: 10. 1038/nbt1205.
133. Poeck H, Ruland J. From virus to inflammation: mechanisms of RIG-I-induced IL-1beta production. Eur J Cell Biol. 2012;91(1): 59-64. doi: 10. 1016/j. ejcb. 2011. 01. 013.
134. Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2, 3-dioxygenase. Immunology. 2009;128(1 Suppl): e837-48. doi: 10. 1111/j. 1365-2567. 2009. 03093. x.
135. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, et al. Engineering mucosal RNA interference in vivo. Mol Ther. 2006;14(3): 336-42. doi: 10. 1016/j. ymthe. 2006. 04. 001.
136. Ocampo SM, Romero C, Aviñó A, Burgueño J, Gassull MA, Bermúdez J et al. (2011) Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice. Mol Ther. 2012;20: 382-90.
137. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319(5863): 627-30. doi: 10. 1126/science. 1149859.
138. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-[alpha] knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 2008;17(1): 162-8.
139. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, Howard KA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. Radiother Oncol. 2010;97(1): 143-8. doi: 10. 1016/j. radonc. 2010. 09. 010.
140. Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9(11): 923-8. doi: 10. 1038/nmat2859.
141. Kriegel C, Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release. 2011;150(1): 77-86. doi: 10. 1016/j. jconrel. 2010. 10. 002.
142. Kriegel C, Amiji MM. Dual TNF-alpha/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin Transl Gastroenterol. 2011;2: e2. doi: 10. 1038/ctg. 2011. 1.
143. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009;458(7242): 1180-4. doi: 10. 1038/nature07774.
144. Zhang J, Tang C, Yin C. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013;34(14): 3667-77. doi: 10. 1016/j. biomaterials. 2013. 01. 079.
145. Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, Shinomura Y, et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol. 2006;209(3): 376-83. doi: 10. 1002/path. 1978.
146. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 2009;27(6): 549-55. doi: 10. 1038/nbt. 1543.
147. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441(7092): 537-41. doi: 10. 1038/nature04791.
148. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7): 1179-87.
149. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008;36(7): 2136-51.
150. Yuan X, Li L, Rathinavelu A, Hao J, Narasimhan M, He M, et al. SiRNA drug delivery by biodegradable polymeric nanoparticles. J Nanosci Nanotechnol. 2006;6(9-10): 2821-8.
151. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target. 2004;12(6): 393-404. doi: 10. 1080/10611860400003858.
152. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA (New York, NY). 2003;9(9): 1034-48.
153. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003;31(2): 589-95.
154. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31(11): 2705-16.
155. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42(26): 7967-75. doi: 10. 1021/bi0343774.
156. Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther. 2007;6(3): 833-43. doi: 10. 1158/1535-7163. mct-06-0195.
157. Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Baas F, et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst. 2010;6(5): 862-70. doi: 10. 1039/b918869j.
158. Nauwelaerts K, Fisher M, Froeyen M, Lescrinier E, Aerschot AV, Xu D, et al. Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides. J Am Chem Soc. 2007;129(30): 9340-8. doi: 10. 1021/ja067047q.
159. Fisher M, Abramov M, van Aerschot A, Rozenski J, Dixit V, Juliano RL, et al. Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol. 2009;606(1-3): 38-44. doi: 10. 1016/j. ejphar. 2009. 01. 030.
160. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20: 495-549. doi: 10. 1146/annurev. immunol. 20. 100301. 064816.